Wall Street trims cancer drug developer BioNTech's unicorn valuation

Wall Street trims cancer drug developer BioNTech's unicorn valuation

Source: 
Endpoints
News Tags: 
snippet: 

Market conditions in the United States are spooking investors. After ADC Therapeutics rescinded its plans earlier this month for a public listing — citing an adverse environment — Germany’s BioNTech on Thursday unveiled its downsized IPO, raising about $100 million less than the $251 million than it had previously envisioned.